BURLINGAME, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), is hosting an investor conference call today to share information on recent developments and progress for its novel NPS platform. The Company will also provide financial results for the three-month period ended March 31, 2017.
Recent Developments
First FDA 510(k) submission for the PulseTxTM System. The PulseTx system is an NPS platform comprised of a tunable nanosecond pulse generator and accompanying tissue applicators. The FDA 510(k) submission made during the first quarter is now under substantive review by the FDA.
Treatment of first patient in canine oral melanoma study. The first patient was treated in the Company’s NPS veterinary medicine pilot study treating solid malignant tumors in canines.
Publication of preclinical research in the Journal for ImmunoTherapy of Cancer. Data demonstrating NPS’ ability to trigger immunogenic cell death (ICD) was recently published in the paper “Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death,” in the peer-reviewed Journal for ImmunoTherapy of Cancer. This paper highlighted the expression of key DAMPS indicative of immunogenic cell death.
“We are very pleased with our ongoing progress over the weeks since our last update,” said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. “We continue to make meaningful progress in developing our technology and pursuing clinical applications for the benefit of patients and clinicians.”
